SMITH & NEPHEW PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,033 GBX | -0.48% |
|
+5.12% | -4.07% |
| Jun. 05 | UBS Upgrades Smith & Nephew to Buy from Neutral, Raises PT | MT |
| Jun. 05 | European blue-chips up ahead of likely rate cuts | AN |
Financials (USD)
| Sales 2024 * | 5.81B | Sales 2025 * | 6.12B | Capitalization | 11.52B |
|---|---|---|---|---|---|
| Net income 2024 * | 527M | Net income 2025 * | 691M | EV / Sales 2024 * | 2.43 x |
| Net Debt 2024 * | 2.61B | Net Debt 2025 * | 2.3B | EV / Sales 2025 * | 2.26 x |
| P/E ratio 2024 * |
23.2
x | P/E ratio 2025 * |
17.2
x | Employees | 18,452 |
| Yield 2024 * |
2.86% | Yield 2025 * |
3.22% | Free-Float | 99.15% |
More Fundamentals
* Assessed data
More news
Latest transcript on Smith & Nephew Plc
More press releases
More news
| 1 day | +0.34% | ||
| 1 week | +4.81% | ||
| Current month | +4.81% | ||
| 1 month | +3.64% | ||
| 3 months | -3.71% | ||
| 6 months | -1.00% | ||
| Current year | -3.76% |
1 week
983.60
1 046.50
1 month
967.801 046.50
Current year
946.001 181.50
1 year
887.001 269.00
3 years
887.001 601.50
5 years
887.002 023.00
10 years
881.002 023.00
| Managers | Title | Age | Since |
|---|---|---|---|
Deepak Nath
CEO | Chief Executive Officer | - | 22-03-31 |
John Rogers
DFI | Director of Finance/CFO | 56 | Nov. 30 |
Alison Parkes
CMP | Compliance Officer | - | 99-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Marc E. Owen
BRD | Director/Board Member | 65 | 17-09-30 |
Jeremy Maiden
BRD | Director/Board Member | 62 | 23-09-13 |
Rupert Soames
CHM | Chairman | 63 | 23-04-25 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.16% | 15 M€ | -3.61% | ||
| 0.52% | 11 M€ | +0.83% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-10 | 1,035 | -0.32% | 123 607 |
| 24-06-07 | 1,038 | +0.34% | 1,818,223 |
| 24-06-06 | 1,034 | +0.63% | 2,163,397 |
| 24-06-05 | 1,028 | +3.30% | 6,031,763 |
| 24-06-04 | 995.2 | +1.12% | 2,065,338 |
Delayed Quote London S.E., June 07, 2024 at 11:35 am EDT
More quotes
Smith & Nephew Plc specializes in designing, manufacturing and marketing medical products and equipment. Net sales break down by activity sector as follows:
- orthopedic surgery (39.9%): primarily orthopedic implants (hips, knees and shoulders);
- sports medicine, arthroscopy and cervicofacial surgery (31.2%): surgery and damaged tissue repair products and instruments, visualization products, etc.;
- wound care (28.9%): skin grafts for major burns victims, treatments for leg ulcers, etc.
The United States accounts for 53.7% of net sales.
Calendar
2024-07-24
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
13.21
USD
Average target price
16.45
USD
Spread / Average Target
+24.58%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.76% | 11.52B | |
| +16.65% | 133B | |
| -4.86% | 8.3B | |
| -22.44% | 4.69B | |
| +7.79% | 3.42B | |
| -17.26% | 2.54B | |
| -13.36% | 2.03B | |
| -16.39% | 1.86B | |
| -31.24% | 1.59B | |
| -8.10% | 1.17B |
- Stock Market
- Equities
- SN. Stock
